Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 587,248
  • Shares Outstanding, K 93,214
  • Annual Sales, $ 837,600 K
  • Annual Income, $ -127,300 K
  • EBIT $ -77 M
  • EBITDA $ 41 M
  • 60-Month Beta 1.99
  • Price/Sales 0.70
  • Price/Cash Flow 6.34
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 271.09% ( -33.79%)
  • Historical Volatility 82.94%
  • IV Percentile 97%
  • IV Rank 78.58%
  • IV High 331.38% on 10/22/25
  • IV Low 49.89% on 11/21/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 45
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 3,397
  • Open Int (30-Day) 3,133

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 5
  • High Estimate -0.07
  • Low Estimate -0.13
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.10 +3.28%
on 11/07/25
8.59 -26.66%
on 10/16/25
-1.23 (-16.33%)
since 10/07/25
3-Month
5.22 +20.57%
on 08/20/25
8.59 -26.66%
on 10/16/25
+0.20 (+3.28%)
since 08/07/25
52-Week
3.76 +67.55%
on 08/01/25
19.60 -67.86%
on 11/08/24
-11.37 (-64.35%)
since 11/07/24

Most Recent Stories

More News
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference

SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies...

MYGN : 6.30 (-0.47%)
Why Myriad Genetics (MYGN) Stock Is Down Today

Why Myriad Genetics (MYGN) Stock Is Down Today

MYGN : 6.30 (-0.47%)
MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds

MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds

MYGN : 6.30 (-0.47%)
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops

Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops

MYGN : 6.30 (-0.47%)
Myriad: Q3 Earnings Snapshot

Myriad: Q3 Earnings Snapshot

MYGN : 6.30 (-0.47%)
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent...

SOPH : 4.37 (-7.81%)
MYGN : 6.30 (-0.47%)
What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings

What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings

MYGN : 6.30 (-0.47%)
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the...

MYGN : 6.30 (-0.47%)
1 Stock Under $10 Worth Your Attention and 2 Facing Challenges

1 Stock Under $10 Worth Your Attention and 2 Facing Challenges

TH : 6.41 (-1.69%)
DDD : 2.22 (-1.33%)
MYGN : 6.30 (-0.47%)
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference...

MYGN : 6.30 (-0.47%)

Business Summary

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made...

See More

Key Turning Points

3rd Resistance Point 6.67
2nd Resistance Point 6.52
1st Resistance Point 6.41
Last Price 6.30
1st Support Level 6.14
2nd Support Level 5.99
3rd Support Level 5.88

See More

52-Week High 19.60
Fibonacci 61.8% 13.55
Fibonacci 50% 11.68
Fibonacci 38.2% 9.81
Last Price 6.30
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar